StudyRareStudyRare

Lysosomal enzyme targeting and recycling

Log in to star
Lysosomes

Last updated Nov 4, 2026

Log in to add personal notes on this page.

Lysosomes are the cell's recycling centers, filled with acid hydrolases that break down waste lipids, proteins, and sugars. Nearly every newly made enzyme is tagged with mannose-6-phosphate in the Golgi, the routing signal that sends it to the lysosome; without the tag it is secreted out of the cell. This page covers the two ends of that system: the tag that delivers the enzymes, and the lysosomal proteins whose loss leaves ceroid lipofuscin behind. The single-enzyme storage disorders are on the glycosaminoglycan and sphingolipid pages.

N-acetylglucosamine-1-phosphotransferaseGNPTAB, GNPTG; tags selectedmannose residues; the gamma subunit(GNPTG) helps it recognize themI-cell diseasean uncovering enzymetrans-Golgi; removes theN-acetylglucosaminemannose-6-phosphate receptorscarry the enzyme to the lysosomethe delivered hydrolases andlysosomal proteins: the PPT1 enzyme,tripeptidyl peptidase 1, batteninPPT1, TPP1, CLN3; at acid pHneuronal ceroid lipofuscinosesnewly made enzymein the Golgisecreted whenuntaggedmannose residuestagged (part one)mannose-6-phosphate exposedenzyme in thelysosomewaste broken downand recycled
Figure: a new lysosomal enzyme is tagged in the Golgi, delivered to the lysosome, and does its work there, with I-cell disease at the tagging step and the neuronal ceroid lipofuscinoses at the recycling step.
  1. A newly made lysosomal enzyme reaches the Golgi apparatus, where it is tagged for the lysosome.
  2. Tagging, part one: N-acetylglucosamine-1-phosphotransferase, alpha and beta subunits from GNPTAB (a gamma subunit from GNPTG helps it recognize its targets), transfers N-acetylglucosamine-1-phosphate to selected mannose residues. Blocked in I-cell disease.
  3. Tagging, part two: in the trans-Golgi, an uncovering enzyme removes the N-acetylglucosamine and exposes mannose-6-phosphate.
  4. Delivery: mannose-6-phosphate receptors carry the enzyme to the lysosome.
  5. Degradation and recycling inside the lysosome, at acid pH, by the delivered hydrolases and by lysosomal proteins such as the PPT1 enzyme (PPT1), tripeptidyl peptidase 1 (TPP1), and battenin (CLN3). Blocked in the neuronal ceroid lipofuscinoses.
  • I-cell disease (mucolipidosis II alpha/beta, AR): with no phosphotransferase, many lysosomal enzymes are secreted at once instead of delivered. Activity rises in plasma and falls inside cultured fibroblasts, and undegraded macromolecules fill lysosomes as dense inclusions. The picture resembles a severe mucopolysaccharidosis, with death most often in early childhood. Variants that keep 1% to 10% of activity give the milder mucolipidosis III alpha/beta.
  • Neuronal ceroid lipofuscinoses (mostly AR; CLN4 from DNAJC5 is AD): ceroid lipofuscin, a waste of lipids and proteins, builds up in lysosomes, above all in neurons of the retina and brain. Vision loss, regression, dementia, epilepsy, and movement disorder follow, with the gene setting onset: CLN1 (PPT1) at 6 to 18 months, CLN2 (TPP1) at 2 to 4 years with seizures, the CLN3 form at 4 to 7 years with vision loss first.
  • Plasma lysosomal enzymes high, fibroblast enzymes low is the signature of mistargeting, because the untagged enzymes leave the cell; arylsulfatase A can be about 90 times normal in plasma in mucolipidosis II. Enzyme levels do not separate mucolipidosis II from III.
  • Urine glycosaminoglycans are normal or only mildly raised in I-cell disease by routine methods, which separates it from a mucopolysaccharidosis with a similar body.
  • Electron microscopy pattern follows the NCL gene: granular osmiophilic deposits in CLN1, curvilinear profiles in CLN2, fingerprint bodies in the CLN3 form. Today it is used mainly to settle a variant of uncertain significance, as are the PPT1 and TPP1 enzyme assays.
  • The common CLN3 1.02-kb deletion can be missed by exome or short-read genome sequencing, so a normal result does not exclude the CLN3 form.
  • CLN2 disease is the one with targeted therapy: recombinant TPP1 enzyme (cerliponase alfa), given into the brain ventricles every 2 weeks, slows motor and language decline.